Raxone is a medicine used to treat visual impairment in adults and adolescents aged 12 years and over with Leber's hereditary optic neuropathy (LHON), an ...
LEROS is an open-label interventional Phase IV study, designed to further assess the efficacy and safety of Raxone® in the long-term treatment of LHON patients.
Idebenone (Raxone®) is recommended for use within NHS Wales for the treatment of visual impairment in adolescent and adult patients with Leber's Hereditary ...
Idebenone (pronounced eye-deb-eh-known, trade names Catena, Raxone, Sovrima, among others) is a drug that was initially developed by Takeda Pharmaceutical ...
#12.
Santhera Announces Phase 4 LEROS Trial with Raxone® Met ...
Raxone ® (idebenone), a synthetic short-chain benzoquinone and a cofactor for the enzyme NAD(P)H:quinone oxidoreductase (NQO1), has shown to ...
#13.
Santhera Concludes Agreement with French ... - Yahoo Finance
Since its introduction in 2015, Raxone was available to patients in France for the treatment of LHON and reimbursed under a temporary financing ...
#14.
Raxone: A Guide for the Community - Action Duchenne
Raxone (also known as Idebenone) is a drug produced by Santhera Pharmaceuticals, which treats several conditions and has the potential to treat Duchenne ...
#16.
Early access to medicines scheme (EAMS) scientific opinion
Renewal of EAMS scientific opinion issued to Santhera Pharmaceuticals for Raxone to treat the decline of respiratory function in patients with Duchenne ...
#17.
Santhera licences LHON drug Raxone to Chiesi Group
Santhera Pharmaceuticals has licensed a drug called Raxone meant for the treatment of Leber's hereditary optic neuropathy (LHON) to Chiesi ...
#18.
Positive Phase IV results for Santhera and Chiesi's Raxone
The primary endpoint, proportion of eyes with clinically relevant benefit after 12 months treatment with Raxone versus untreated patients ...
#19.
BRIEF-Santhera: MHRA Renews Early Access ... - Reuters
UK'S MHRA RENEWS EARLY ACCESS TO MEDICINES SCHEME SCIENTIFIC OPINION FOR SANTHERA'S RAXONE® (IDEBENONE) IN DUCHENNE MUSCULAR DYSTROPHY ...
Pakningsvedlegg: Informasjon til brukeren. Raxone 150 mg filmdrasjerte tabletter. idebenon. Dette legemidlet er underlagt særlig overvåking for å oppdage ny ...
#21.
Raxone (Idebenone) Shows Promise as DMD Therapy in ...
Long-term treatment with idebenone (Raxone) may slow down the loss of respiratory function in Duchenne muscular dystrophy patients for up to ...
#23.
Clinical experience with Idebenone (Raxone®) in the ... - IOVS
This study reports VA outcomes for LHON patients with recent onset of vision loss who received idebenone (Raxone) treatment under an Expanded Access Program ( ...
Raxone. The medicinal product has been authorised by the European Commission (EC) via centralised procedure in all EU Member States, based on the European ...
Raxone. This page shows the latest Raxone news and features for those working in and with pharma, biotech and healthcare. Encouraging data for GenSight's ...
#27.
Chiesi's Raxone recommended for use within NHS Wales
Chiesi's rare disease medicine Raxone has been recommended for use within NHS Wales for the treatment of visual impairment in adolescent and ...
Raxone (idebenone) is used to treat visual impairment in adults and adolescents aged 12 years and over with Leber's hereditary optic neuropathy (LHON), an ...
#29.
Chiesi acquires ex-US Raxone marketing rights
Chiesi Farmaceutici has licenced commercialiation rights for LHON treatment Raxone (idebenone) from Santhera Pharmaceuticals for CHF50m ...
#30.
Santhera Announces Successful Outcome of Phase III Study ...
Santhera develops Catena(R)/Raxone(R) as treatment for patients with Leber's Hereditary Optic Neuropathy (LHON), Duchenne Muscular Dystrophy (DMD) and ...
#34.
Update on stoppage of SIDEROS clinical trial for Raxone ...
In October we published news that Santhera, the company developing Raxone/idebenone (a potential treatment for delaying the loss of ...
#35.
Real world data collection on the efficacy and drug usage of ...
Real world data collection on the efficacy and drug usage of Raxone 150 mg 180 film-coated tablets for treatment of reduced vision in adolescent ...
#36.
NCPE Idebenone (Raxone®) Assessment
Brand, Raxone®. Indication, For the treatment of visual impairment in adolescent and adult patients with Leber's Hereditary Optic Neuropathy ...
#37.
Raxone (idebenone) in LHON - An update
Download Citation | Raxone (idebenone) in LHON - An update | Leber's Hereditary Optic Neuropathy (LHON) is caused by mtDNA mutations affecting subunits of ...
#38.
Chiesi pays $105m to license ophthalmological drug
According to Santhera, Chiesi Farmaceutici also has the option to fully acquire Raxone (idebenone) upon the completion of reimbursement and post ...
#39.
219 First year of the early access to medicines scheme for ...
Under EAMS Raxone is administered under routine clinical practice. In the second year additional data collection has been introduced to obtain information on ...
#40.
Raxone | MIMS online
Raxone. Section: Eye; Sub Section: Diagnostic and surgical; Drug Class: Retinal disorder treatments; Manufacturer: Santhera (UK) Ltd.
#41.
Register of Medicinal Products - Ravimiregister
Raxone is indicated for the treatment of visual impairment in adolescent and adult patients with Leber's Hereditary Optic Neuropathy (LHON) (see section 5.1).
#42.
Informe de Posicionamiento Terapéutico de Idebenona ...
Informe de Posicionamiento Terapéutico de Idebenona (Raxone®) en el tratamiento de Neuropatía Óptica Hereditaria de Leber (NOHL).
#43.
Raxone 150 mg comprimidos recubiertos con película - CIMA
Raxone contiene un principio activo denominado idebenona. Idebenona se utiliza para tratar la alteración visual en adultos y adolescentes con una enfermedad de ...
#44.
Raxone - information til sundhedsfaglige - Medicin.dk
#45.
Raxone - News, Articles etc. - European Pharmaceutical Review
News stories and articles referencing Raxone on European Pharmaceutical Review.
#46.
Idebenone (Raxone°) and Leber hereditary optic neuropathy ...
In the February issue of Prescrire International: Idebenone (Raxone°) and Leber hereditary optic neuropathy. FREE DOWNLOAD In this month's ...
#47.
Raxone – Medicinal Product Register of Latvia - ZVA IS dati
Medicinal product name, Raxone. Pharmaceutical form, Film-coated tablet. Strength, 150 mg. Information from the MAH on shortages ...
#48.
Idebenone (Raxone®) for the treatment of Leber's Hereditary ...
Zorginstituut Nederland has carried out an assessment of the medicinal product idebenone. (Raxone®), whereby they came to the following ...
#49.
Santhera Shores Up Finances With Chiesi Deal for Raxone
In a deal that could be worth CHF105m, the Swiss biotech has outlicensed Raxone to Chiesi for the rare eye disease LHON as it concentrates ...
#50.
Idebenone (Raxone) - GNH India
Buy Idebenone (Raxone) 150 mg. Get quick delivery of medicines online from GNH India at the best price. GNH India is a Global Pharmaceuticals Distributor ...
#51.
Raxone (Idebenone 150mg) - Swiss Biotech Association
Raxone (Idebenone 150mg) · Indicaton · Company · Therapeutic indications · Table · Type of product.
#52.
Australian Public Assessment Report for Idebenone
AusPAR Raxone - idebenone - JACE Pharma Pty Ltd - PM-2017-01423-1-3 – FINAL 6 February 2020. Page 2 of 91. About the Therapeutic Goods Administration (TGA).
#53.
UK regulators green-light early access to Santhera's Raxone ...
We expect a positive CHMP recommendation and label expansion to DMD given: 1) Raxone is the only DMD therapy with a positive Phase III trial; 2) ...
#54.
Santhera Concludes Agreement with ... - PharmiWeb.com
Santhera Concludes Agreement with French Authorities on Raxone® Reimbursement and Plans to Submit a Request for an Early Access Program for ...
#55.
EAMS Treatment Protocol - Information for HCP - GOV.UK
Raxone is not currently approved for use in DMD patients taking concomitant glucocorticoids and should not be prescribed to such patients. Special populations.
#56.
RAXONE, 150MG TBL FLM 180, Státní ústav pro kontrolu léčiv
Text na obalu, raxone-epar-product-information_cs.pdf. Braillovo písmo, Schváleno – text na obalu odpovídá zákonným požadavkům.
#57.
Santhera Updates on Regulatory Filings for Raxone ...
We're here to transform the lives of people affected by neuromuscular disease. Santhera Updates on Regulatory Filings for Raxone® (idebenone) in Duchenne ...
#58.
Santhera facing long delay for muscular dystrophy drug in US
Santhera has hoped to use the truncated approval pathway to gain approval for Raxone in DMD patients not taking glucocorticoid drugs based on ...
Santhera resubmitted an MAA to EMA for Raxone idebenone to treat Leber's hereditary optic neuropathy (LHON). The company withdrew an MAA for ...
#60.
Santhera Pharma teams up with Ewopharma to launch ...
Santhera Pharma teams up with Ewopharma to launch Raxone in Eastern European & Baltics countries to treat LHON.
#61.
Pubblicazione schede di monitoraggio Registro RAXONE - AIFA
Pubblicazione schede di monitoraggio Registro RAXONE Si informano gli utenti dei Registri Farmaci sottoposti a Monitoraggio che, ...
#62.
International team advises Chiesi Farmaceutici on in-licence ...
International law firm Bird & Bird has advised Chiesi Farmaceutici S.p.A. ("Chiesi") on the in-licence of Raxone® -- an orphan drug used in ...
#63.
Santhera's Raxone® Receives First Positive EAMS Scientific ...
Duchenne UK is pleased to share news from Santhera Pharmaceuticals regarding the progress of Raxone. The body that approves new drugs in the ...
#64.
Raxone - FASS Vårdpersonal
Idebenon, en kortkedjig bensokinon, är en antioxidant som antas kunna överföra elektroner direkt till komplex III av den mitokondriella elektrontransportkedjan, ...
#66.
Raxone - European Pharmaceutical Manufacturer
Santhera Pharmaceuticals has announced that the MHRA has granted a positive scientific opinion through the Early Access to Medicines Scheme (EAMS) to Raxone ...
#67.
MS Therapy Raxone's Safety Profile Confirmed in NIH Trial
Read about a Phase 1/2 trial confirming the safety profile of Santhera's PPMS therapy Raxone. The National Institutes of Health conducted ...
Raxone is indicated for the treatment of visual impairment in adolescent and adult patients with Leber's Hereditary Optic Neuropathy (LHON) ...
#69.
Raxone : Uses, Side Effects, Interactions, Dosage / Pillintrip
Raxone is indicated for the treatment of visual impairment in adolescent and adult patients with Leber's Hereditary Optic Neuropathy (LHON).
#70.
Idebenone (Raxone) Fails in Exploratory MS Trial - Medscape
An exploratory phase 1/2 clinical trial of idebenone (Raxone, Santhera Pharmaceuticals) in patients with primary progressive multiple ...
#71.
Santhera shares slide as Raxone fails in MS study
Santhera Pharmaceutical Holding AG's drug Raxone failed to demonstrate any benefit over placebo in a small study of patients with primary ...
#72.
Raxone dans la neuropathie optique de Leber
Leber's Hereditary Optic Neuropathy (LHON) causes a rapid and severe decrease in visual acuity. Raxone® (Idebenone, Santhera) is the only drug to have a ...
#73.
a guide for clinicians - About the treatment - What is Raxone?
Summary. Raxone is believed to help slow down the decline in respiratory function by slowing the rate at which the respiratory muscles weaken, by improving ...
#74.
Study to Assess the Efficacy and Safety of ... - CenterWatch
Clinical trial for Leber's Optic Atrophy , Study to Assess the Efficacy and Safety of Raxone in LHON Patients.
#75.
Advice to Chiesi Farmaceutici on in-licence of Raxone® from ...
BianchiSchwald provided Chiesi Farmaceutici S.p.A. (“Chiesi”) with Swiss law advice in relation to its in-licencing of Raxone®– an orphan ...
#76.
RAXONE, 150MG TBL FLM 180, State Institute for Drug Control
Text on the wrap, raxone-epar-product-information_cs.pdf. Braills, Approved – name of the medicinal product in Braille on the packaging was confirmed.
#77.
Idebenon (Raxone) til behandling av duchenne muskeldystrofi ...
Produktnavn: Raxone. Produsent: Santhera Pharmaceutical. Søketermer/synonymer: Status for bruk og godkjenning.
#78.
Raxone RMP summary - PHAST
There are no important identified risks for Raxone. Important potential risks. Risk. What is known. Abnormal liver function test and hepatitis (liver disease).
#79.
Santhera Making Raxone Available to DMD Patients in US ...
Raxone is not approved to treat Duchenne MD by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).
#80.
Raxone (Idebenone) - Budapest - somlaijudit.hu
Raxone (Idebenone) expansion of the indication clinical - medicinal treatment. Secondary Opticopathy (prechiasmal , non-genetic) disorders group.
#81.
[Raxone in the Leber optical neuropathy: Parisian experience].
INTRODUCTION:Leber's Hereditary Optic Neuropathy (LHON) causes a rapid and severe decrease in visual acuity. Raxone® (Idebenone, Santhera) ...
#82.
Raxone DMD application validated by EMA - LinkedIn
Santhera's Marketing Authorization Application for Raxone ® in Duchenne Muscular Dystrophy (DMD) Validated by the European Medicines Agency.
#83.
Santhera launches Raxone® for treatment of LHON in its first ...
Santhera Pharmaceuticals (SIX: SANN) announces that it is today launching Raxone® for the treatment of Leber's Hereditary Optic Neuropathy ...
#84.
Raxone dans la neuropathie optique de Leber - EM consulte
Raxone ® (Idébénone, Santhéra) est le seul médicament à disposer d'une AMM européenne dans le traitement de cette neuropathie optique.
#85.
Raxone - Idebenone - My-personaltrainer.it
Raxone è un medicinale indicato per il trattamento della compromissione visiva in adulti e adolescenti a partire dai 12 anni di età affetti ...
#86.
RAXONE - VIDAL
Retrouvez sur VIDAL la gamme de médicaments RAXONE avec ses spécialités, l'information patient. ... fiche abrégée RAXONE 150 mg cp pellic.
#87.
Santhera Receives European Marketing Authorization for ...
"The European approval of Raxone as an efficacious treatment for LHON and as the first approved medication for a mitochondrial disease is a ...
#88.
Raxone Approved for Leber's Hereditary Optic Neuropathy in ...
Raxone (idebenone) was approved in Israel as a treatment for visual impairment due to Leber's hereditary optic neuropathy (LHON), ...
Popis Raxone 150 mg tbl flm (fľ.HDPE) 1x180 ks: Liek obsahuje liečivo, ktoré sa nazýva idebenón. Idebenón môže u pacientov reaktivovať životaschopné, ...
#91.
Raxone_INN- idebenone
Raxone was designated an 'orphan medicine' (a medicine to be used in rare diseases) on 20 March. 2007 for Duchenne muscular dystrophy. Further ...
#92.
Efficacy of Catena®/Raxone® (Idebenone) on Respiratory ...
Efficacy of Catena®/ Raxone ® (Idebenone) on Respiratory Outcome in Duchenne (October 2014). Parent Project Muscular Dystrophy by: Parent Project ...
#93.
Φάρμακο - RAXONE - Γαληνός
Αναλυτικές πληροφορίες συστατικών, κυκλοφορίας και τρόπου χρήσης του φαρμάκου RAXONE.
A Raxone egy idebenon nevű hatóanyagot tartalmaz. Az idebenon a látásromlás kezelésére szolgál a Leber-féle örökletes optikus neuropátia (LHON) nevű ...
raxone 在 Raxone - Santhera [PPMD's 2017 Connect Conference] 的推薦與評價
Trial Update: Raxone - Santhera [PPMD's 2017 Connect Conference]. 660 views 5 years ago. Parent Project Muscular Dystrophy. ... <看更多>